Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Viatris Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.74, while Viatris Inc trades at $16.36 (market cap $18.94B). The key difference: Viatris Inc pays a 2.95% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Viatris Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | VTRS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $16.61 | $17.39 |
52-Week Low | $10.26 | $8.74 |
Market Cap | — | $18.94B |
Enterprise Value | — | $31.15B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
Viatris (VTRS) trades at $16.27, down 0.43% on the day, with a bullish technical signal supported by moving averages. The stock has beaten EPS estimates for the last three quarters, though it reported a net loss of $3.51B in 2025. Revenue has declined from $16.3B in 2022 to $14.3B in 2025. Positive news includes FDA acceptance of a new drug application for fast-acting meloxicam and a Phase 3 study success for VR-205, targeting a Japanese NDA by end of 2026.
The outlook is mixed: analyst consensus is a $20 price target with a 'Hold' bias, but high debt and negative margins pose risks. Upside potential hinges on pipeline success and debt reduction, while competitive pressures and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
